Print Page  Close Window

Investor Overview

Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.2 (1.79%)
Data as of 07/17/18 12:35 p.m. ET
Refresh quote
Recent NewsMore >>
06/04/18Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018™
05/30/18Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
05/24/18Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock
05/23/18Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock
Upcoming EventsMore >>
Eiger BioPharmaceuticals at the Wedbush PacGrow Conference
Eiger BioPharmaceuticals at the Rodman and Renshaw Conference
Eiger BioPharmaceuticals at the Ladenburg Thalmann 2018 Healthcare Conference
LocationNew York City, NY
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed.